**Question:** A 30-year-old patient presents with a history of persistent antibodies to HCV for a duration of 6 months, normal AST/ALT, and no symptoms or signs of liver disease. The most suitable management strategy:

A. Liver biopsy
B. Monitoring
C. Further evaluation and treatment
D. No intervention

**Correct Answer: B. Monitoring**

**Core Concept:**
The question is evaluating the management approach for a patient with chronic hepatitis C virus (HCV) infection, characterized by the presence of HCV antibodies for a duration of 6 months, normal liver enzymes (AST and ALT), and absence of clinical symptoms or liver disease signs. This highlights the need to balance between active treatment and close monitoring in this patient population.

**Why the Correct Answer is Right:**
In this scenario, the patient's liver enzymes (AST and ALT) are normal, indicating that the liver is not being damaged at the current stage. This is crucial as liver enzymes are often elevated in patients with liver disease due to HCV infection. Additionally, the patient does not exhibit any symptoms or liver disease signs, suggesting that active intervention may not be necessary at this stage.

**Why Each Wrong Option is Incorrect:**
A) Liver biopsy: Although liver biopsy could provide valuable information about liver damage, it is unnecessary in this patient as no clinical evidence of liver disease is present.

B) Further evaluation and treatment: The patient does not have clinical symptoms or liver disease signs, and normal liver enzymes further support the observation period.

C) No intervention: The patient's normal liver enzymes and absence of symptoms or signs of liver disease indicate that intervention might not be necessary at this stage.

**Clinical Pearl:**
In cases of chronic HCV infection, close monitoring with regular liver enzyme tests and clinical evaluation is recommended to identify any changes in disease progression at an early stage. Waiting for active treatment initiation depends on the patient's response to the monitoring process. In this case, no intervention is necessary at this stage, and monitoring is recommended for early detection of disease progression or the emergence of symptoms/liver enzyme abnormalities.